

## Index to Volume Twenty-two

Index of Issues: January–February, 1–70; March–April, 71–136; May–June, 137–202;  
July–August, 203–268; September–October, 269–328; November–December, 329–390.

### INDEX OF AUTHORS

#### A

Agnew KJ, 269  
Aral S, 162, 169

#### B

Bai H, 383  
Beach R, 236  
Bergström T, 210  
Bianchi A, 244  
Black C, 197  
Blanco DR, 31  
Blomberg J, 1  
Bo N, 383  
Bodén E, 119, 355  
Bodner J, 55  
Bolan G, 169, 335  
Borenstein LA, 31  
Bouleret A, 228  
Brathwaite AR, 114, 155  
Breese PL, 7  
Briggs LP, 348  
Brockmann S, 344  
Burger MPM, 296  
Burk RD, 114

#### C

Camarena JJ, 128  
Campos-Outcalt D, 78  
Campsmith ML, 312  
Carmody CJ, 310  
Casin I, 244  
Celentano D, 15  
Champion CI, 31  
Chastang C, 244  
Chattopadhyaya D, 25  
Chernesky MA, 55  
Chieza L, 1  
Chong S, 55  
Chout RT, 221  
Chow JM, 191, 317  
Christenson B, 281  
Clarke L, 344  
Cohen MS, 145  
Coleman P, 55  
Covino JM, 110  
Cummings MC, 110

#### D

Danella RD, 173  
Dasi MA, 128  
Davis RH, 145  
Donegan E, 335  
Dong, LZ, 383  
Donovan B, 310  
Douglas JM, Jr, 7  
Douglas JM, Jr, 236  
Draft K, 110  
Duncan W, 155  
Duran R, 97  
Duval-Violton D, 221

Dwyer DM, 364

#### E

Eager R, 236  
Edlund K, 119, 355  
Egger M, 253  
Eichmann AR, 296  
Eldridge GD, 231  
Ellish N, 15  
Engelgau MM, 203  
Ernst AA, 217  
Etkind P, 348  
Evander M, 119, 355  
Eweiss NYM, 317

#### F

Feldman J, 344  
Felsenstein D, 67  
Figueroa JP, 114

#### G

Garcia R, 128  
Gayek RJ, 31  
Goldbaum GM, 312  
Gorsky RD, 203  
Grant RM, 351  
Greenspan JR, 60, 203, 329  
Grillot P, 244  
Groseclose SL, 197  
Gukkus SD, 329  
Gunn RA, 60, 329  
Gupta MM, 25  
Gustavsson Å, 119, 355

#### H

Haddix AC, 274  
Haizlip J, 145  
Hamilton HA, 145  
Hamman R, 236  
Hammond G, 289  
Hellman N, 351  
Hermodsson S, 210  
Hermonat PL, 22  
Hernandez J, 128  
Herrmann B, 253  
Hessol N, 335  
Hillier SL, 269  
Hillis S, 197, 274  
Hillis SD, 328  
Hinds A, 155  
Hoff GL, 377  
Hollema H, 296  
Hook EW, III, 15, 322  
Hrusovsky I, 55  
Huan L, 383

#### I

Isbey SF, 145  
Israel E, 364

#### J

Jacoby HM, 380

Jamison JH, 236  
Jang D, 55  
Janier M, 244  
Jerse AE, 145  
Jolly AM, 289  
Jonsson M, 119, 355  
Jonte J, 335  
Judson FN, 7  
Juto P, 355

#### K

Kamya MR, 351  
Kaplan DW, 236  
Karlsson R, 119, 355  
Kassler WJ, 274  
Kaufmann JA, 67  
Kirby LJ, 310  
Knapp JS, 155  
Korn AP, 335  
Krieger JN, 83

#### L

Landers DV, 335  
Landesman S, 344  
Lassau F, 244  
Latman AI, 104  
Latman NS, 104  
Ledesma E, 128  
Leguyader-Despres P, 221  
Leone PA, 145  
Lewinski MA, 31  
Limnios EA, 310  
Lindholm A, 210  
Linglöff T, 160  
Llorca J, 128  
Lovett MA, 31  
Luthi TE, 114  
Lynch SD, 310

#### M

Mady BJ, 380  
Mahoney JB, 55  
Marti B, 303  
Martin DH, 217  
Marvez-Valls E, 217  
Matuszak D, 364  
McCormack WM, 110  
Mehanna MTR, 317  
Miller H, 162  
Miller JN, 31  
Minkoff H, 344  
Montes JM, 60  
Moran JS, 39, 67  
Morel P, 244  
Moreno F, 128  
Moses S, 231  
Moyo SR, 1  
Muzsnai D, 335

#### N

Nakashima A, 364

Newhall J, 197  
Ngugi EN, 231  
Njeru EK, 231  
Nsuguba P, 351  
Nogueira JM, 128  
Norkrans G, 210  
Nyström L, 1  
Nzara M, 1

#### O

O'Cain M, 203  
O'Donnell CR, 97  
O'Donnell L, 97  
O-Prasertsawat P, 228  
Orfila J, 221  
Orr PH, 289

#### P

Padian NS, 169  
Padian N, 335  
Paget WJ, 303  
Paisarntantiwong R, 344  
Parashari A, 25  
Pate MS, 322  
Patnaude P, 348  
Patton DL, 48  
Pearce H, 364  
Penley KA, 7  
Persson K, 355  
Peterman TA, 164  
Peters N, 296  
Pieters WJLM, 296  
Plummer FA, 231

#### Q

Quint WGV, 296

#### R

Ramadan M, 317  
Rank RG, 48  
Ratiu ES, 110  
Rice RJ, 155  
Rizk MA, 317  
Rogers SM, 173  
Rofls RT, 60, 203  
Rompalo AM, 15  
Ryan K, 78  
Rylander E, 119, 355

#### S

Sadek A, 317  
San Doval A, 97  
Sanders MM, 48  
Satyanarayana, L, 25  
Scavron J, 348  
Schachter J, 191, 317, 335  
Schwebke JR, 370  
Scieux C, 244  
Sehgal A, 25  
Sellors J, 55  
Shev S, 210

Shirey, P, 329  
Singh V, 25  
Smith BL, 110  
Smucker DR, 149  
Sodhani P, 25  
Sokal DC, 22  
Soper DE, 342  
Spitters CE, 60  
Stillström J, 281

## T

Tapsall JW, 310  
Thacker C, 310  
Thomas JC, 149  
Thompson BL, 364

Tianani J, 1  
Toomey KE, 60  
Tswana SA, 1  
Turner CF, 173

## U

Upchurch DM, 15

## V

Van Leeuwen AM, 296  
Vaton S, 221  
Vermund SH, 114  
Vranizan K, 169

## W

Wadell G, 119, 355  
Walker EM, 31  
Walsh C, 197  
Ward E, 114  
Waterman SH, 60, 329  
Weisman CS, 15  
Weismann K, 137  
Wells KD, 377  
Whelan M, 348  
Widell A, 210  
Wise KA, 310  
Woernle CH, 203  
Wood RW, 312

World Health Organization Task  
Force on the Prevention  
and Management of  
Infertility, 71

## Y

Young TK, 289

## Z

Zaki SA, 317  
Zavaro A, 244  
Zenilman JM, 15  
Zwahlen M, 296

## INDEX OF SUBJECTS

## A

Acute gonococcal sepsis, in HIV infection, 380  
Adolescents, human papillomavirus infection in, 236  
American Public Health Association  
120th Annual Meeting of, Symposium on Methodologic Issues in,  
162  
news from, 266, 327  
Ampicillin, for vaginitis and cervicitis, *Lactobacilli* colonization af-  
ter, 269  
Anal human papillomavirus infection, HIV infection and, in homo-  
sexuals, 7  
Antibiotic resistance, of *N. gonorrhoeae*, 110  
Antibiotics  
oral vs. intramuscular single-dose, *N. gonorrhoeae* elimination  
time with, 145  
for vaginitis and cervicitis, *Lactobacilli* colonization after, 269  
Antibiotic susceptibility, of *N. gonorrhoeae*, 110  
Arsenic poisoning, vs. neurosyphilis, in Karen Blixen, 137  
Aspiration, of chancroid buboes, vs. incision and drainage, 217  
Azithromycin  
for *C. trachomatis* infections, cost effectiveness of, 274  
for vaginitis and cervicitis, *Lactobacilli* colonization after, 269

## B

Bacterial vaginosis  
antibiotics for, *Lactobacilli* colonization after, 269  
cervical intraepithelial neoplasia and, 296  
Baltic states, STDs in, rapid increase in, 160  
Bias, participation, in research studies, 164, 312  
Bisexuals. See Homosexuals/bisexuals  
Blixen, Karen, neurosyphilis vs. heavy metal poisoning in, 137  
Book reviews  
*Managing Herpes: How to Live and Love with a Chronic STD*  
(Ebel), 265  
*The Secret Years of Venus: A History of Venereology* (Oriol), 265  
Buboes, chancroid, incision and drainage vs. aspiration of, 217

## C

Candidiasis, vulvovaginal, fluconazole vs. clotrimazole for, 228  
Centers for Disease Control, Division of STD/HIV Prevention of, as-  
sessment of, 67  
Cephalosporins, oral vs. intramuscular single-dose, *N. gonorrhoeae*  
elimination time with, 145  
Cervical intraepithelial neoplasia, bacterial vaginosis and, 296  
Cervicitis, antibiotics for, *Lactobacilli* colonization after, 269  
Cervix  
human papillomavirus infection of. See Human papillomavirus infection  
inflammatory epithelial changes in, in reproductive tract infections, 25  
Chancroid, incision and drainage vs. aspiration of buboes in, 217

China, *C. trachomatis* infection prevalence in, 383

*Chlamydia trachomatis*

colonization with, trichomoniasis and PID and, 344  
culture of, laboratory to laboratory variation in, 322  
in male urine and urethral swabs, 55  
*Chlamydia trachomatis* infection  
antibiotics for, *Lactobacilli* colonization after, 269  
azithromycin for, cost effectiveness of, 274  
ectopic pregnancy and, 317  
male urethritis and, 244  
prevalence of  
in China, 383  
in Sweden, 253  
prevention of, new approaches for, 197  
risk factors for, 355  
vs. for gonorrhea, in women, 289  
screening for, in pregnant women, in Martinique, 221  
tubal infertility and, 49, 71, 317

## Client education

for college students, for HIV/AIDS risk reduction, 104  
video-based, for condom acquisition, 97  
Clindamycin, for vaginitis and cervicitis, *Lactobacilli* colonization af-  
ter, 269  
Clinical trials. See Research studies  
Clotrimazole  
for vaginitis and cervicitis, *Lactobacilli* colonization after, 269  
for vulvovaginal candidiasis, vs. fluconazole, 228  
College students, HIV/AIDS risk reduction education for, 104  
Condom use  
promotion of  
for college students, 104  
video-based, 97  
self-reported, validity of, 15  
in STD clinic patients, in Switzerland, 269  
Congenital syphilis, increased incidence of, case definition changes  
and, 364  
Contact notification. See Partner notification  
Crack cocaine users, syphilis in, partner notification for, 60  
Culture, *C. trachomatis*, laboratory to laboratory variation in, 322

## D

Developing countries, partner notification in, 231  
Diagnostic tests, fallibility of, 191  
Dinesin, Isak, neurosyphilis vs. heavy metal poisoning in, 137  
DNA amplification fingerprinting, in *N. gonorrhoeae* subtyping, 128  
Doxycycline  
for *C. trachomatis* infections, cost effectiveness of, vs. for az-  
ithromycin, 274  
for vaginitis and cervicitis, *Lactobacilli* colonization after, 269  
Drug-use history, in STD risk assessment, 348

## E

- Eastern bloc countries, sexually transmitted diseases in, rapid increase in, 160
- Ectopic pregnancy, *C. trachomatis* infection and, 317
- Education, for college students, for HIV/AIDS risk reduction, 104
- Egypt, tubal infertility in, after chlamydial infection, 317
- Endometritis, plasma cell, sensitivity of PID diagnostic criteria for, 335
- Estonia, STDs in, rapid increase in, 160

## F

- Fluconazole  
for vaginitis and cervicitis, *Lactobacilli* colonization after, 269  
for vulvovaginal candidiasis, vs. clotrimazole, 228

## G

- Genital herpes, genital ulcer disease and, in Uganda, 351
- Gonococcal infection  
site of, treatment efficacy and, 39  
tubal infertility and, 71
- Gonococcal sepsis, in HIV infection, 380
- Gonorrhea. *See also* Gonococcal infection; *Neisseria gonorrhoeae*  
acquired immunity to, 261 (letter)  
risk factors for, vs. for *C. trachomatis* infection, in women, 289

## H

- Heavy metal poisoning, vs. neurosyphilis, in Karen Blixen, 137
- Hepatitis C, increased susceptibility to, HSV-2 and, 210
- Herpes simplex virus-2, and increased susceptibility to hepatitis C, 210
- Herpes simplex virus infection, genital, genital ulcer disease and, in Uganda, 351
- Hispanic women  
*C. trachomatis* screening in, 329  
STDs in, during pregnancy, 78
- Homosexuals/bisexuals  
anal human papillomavirus infection in, HIV infection and, 7  
cohort study of, selection bias in, 312
- Human immunodeficiency virus infection  
acute gonococcal sepsis in, 380  
anal human papillomavirus infection and, in homosexuals, 7  
epidemiology of, in Sweden, 281  
partner notification for, in low incidence urban community, 377
- Human papillomavirus, povidone-iodine inactivation of, 22
- Human papillomavirus infection  
in adolescents, 236  
lifetime number of partners and, 119  
prevalence of, in Jamaica, 114

## I

- Infertility, tubal  
past chlamydial infection and, 71, 317  
with single vs. multiple occurrences, 48  
past gonococcal infection and, 71

## J

- Jamaica  
human papillomavirus infection prevalence in, 114  
*N. gonorrhoeae* plasmid-mediated antimicrobial resistance in, 155

## K

- Kenya, partner notification in, 231

## L

- Lactobacilli*, vaginal colonization by, after treatment for vaginitis and cervicitis, 269

- Latvia, STDs in, rapid increase in, 160
- Lithuania, STDs in, rapid increase in, 160

## M

- Martinique, *C. trachomatis* screening in, in pregnant women, 221
- Mercury poisoning, vs. neurosyphilis, in Karen Blixen, 137
- Methodologic issues  
diagnostic test fallibility, 191  
participation bias, 164, 312  
population-based research on sexual behavior, 173  
sexual history reliability, 169  
thought experiments, 261 (letter)
- Metronidazole  
for bacterial vaginosis, 370  
in pregnancy, 370  
for trichomoniasis, 370  
for vaginitis and cervicitis, *Lactobacilli* colonization after, 269
- Mexican-American women  
*C. trachomatis* screening in, 329  
STDs in, during pregnancy, 78

## N

- Needle aspiration, of chancroid buboes, vs. incision and drainage, 217
- Neisseria gonorrhoeae*  
elimination time for, with oral vs. intramuscular single-dose therapy, 145  
penicillin/tetracycline susceptibility of, 110  
quinolone resistance to, 310  
subtyping of, DNA amplification fingerprinting in, 128
- Nisseriae gonorrhoeae*, plasmid-mediated antimicrobial resistance of, in Jamaica, 155
- Neurosyphilis, vs. heavy metal poisoning, in Karen Blixen, 137

## P

- Participation bias, in research studies, 164, 312
- Partner notification  
in control of early epidemic syphilis, 203  
in developing countries, 231  
for HIV infection, in low incidence urban community, 377  
for syphilis, in high-risk population, 60
- Partners, lifetime number of, human papillomavirus infection and, 119
- Pelvic inflammatory disease. *See also* Salpingitis  
definition of, 342  
diagnostic criteria for, 342  
sensitivity of for plasma cell endometritis, 335  
trichomoniasis and, in women colonized with *C. trachomatis*., 344
- Penicillin, *N. gonorrhoeae* susceptibility to, 110
- Pharyngeal gonococcal infection, treatment efficacy in, 39
- Philippines, quinolone-resistant *N. gonorrhoeae* in, 310
- Plasma cell endometritis, sensitivity of PID diagnostic criteria for, 335
- Population-based research, on sexual behavior, 173
- Povidone-iodine, human papillomavirus inactivation by, 22
- Pregnancy  
*C. trachomatis* infection in, screening for, in Martinique, 221  
ectopic, *C. trachomatis* infection and, 317  
metronidazole in, 370  
STDs in, in Mexican-American women, 78
- Prostitutes, syphilis in, partner notification for, 60

## Q

- Quinolone, *N. gonorrhoeae* resistance to, 310

## R

- Reporting, of STDs, in Southern rural county, 149
- Reproductive tract infections, cervical inflammatory epithelial changes in, 25
- Research studies

- methodologic issues in. *See* Methodologic issues  
 participation bias in, 164, 312  
 Risk assessment, for STDs, social history in, 348

## S

- Safe sex practices  
 promotion of  
   for college students, 104  
   video-based, 97  
   self-reporting of, validity of, 15  
   in STD clinic patients, in Switzerland, 269  
 Salpingitis. *See also* Pelvic inflammatory disease  
   infertility and  
   prior chlamydial infection and, 71, 317  
   with single vs. multiple occurrences, 48  
   prior gonococcal infection and, 71  
 Salpingitis, in clinically diagnosed PID, 342  
 Salvarsan, for syphilis, 137  
 Screening, for *C. trachomatis*  
   in Hispanic women, 329  
   in males, 253  
   in pregnant women, in Martinique, 221  
 Selection bias, in research studies, 164, 312  
 Sepsis, acute gonococcal, in HIV-infected female, 380  
 Sexual activity, early, *C. trachomatis* infection and, 355  
 Sexual behavior, population-based research on, 173  
 Sexual history  
   of heterosexual couples, reliability of, 169  
   in STD risk assessment, 348  
 Sexually transmitted diseases. *See also specific diseases*  
   epidemiology of, in Sweden, 281  
   in Mexican-American pregnant women, 78  
   rapid increase in, in Baltic states, 160  
   reporting of, in Southern rural county, 149  
   risk assessment for, social history in, 348  
 Sexual partners  
   multiple, *C. trachomatis* infection and, 305  
   notification of  
     in control of early epidemic syphilis, 203  
     in developing countries, 231  
     for HIV infection, in low incidence urban community, 377  
     for syphilis, in high-risk population, 60  
 Social history, in STD risk assessment, 348  
 Social networks. *See also* Partner notification  
   in control of early epidemic syphilis, 203  
 Soviet Union, STDs in, rapid increase in, 160  
 Students, HIV/AIDS risk reduction education for, 104  
 Studies. *See* Research studies  
 Sweden  
   *C. trachomatis* infection in, declining rates of, 253, 281

- HIV/STD epidemiology in, 281  
 Switzerland, STD clinic patients in, condom use by, 269  
 Syphilis  
   congenital, increased incidence of, case definition changes and, 364  
   epidemic early, control of using social networks, 203  
   vs. heavy metal poisoning, in Karen Blixen, 137  
   immunity to, treponemical antibody and, 31  
   partner notification for, in high-risk population, 60

## T

- Tetracycline, *N. gonorrhoeae* susceptibility to, 110  
 Third world countries, partner notification in, 231  
 Thought experiments, 261 (letter)  
 Treponemical antibody, syphilis immunity and, 31  
 Trichomoniasis  
   in men, 83  
   PID and, in women colonized with *C. trachomatis*., 344  
 Tubal infertility  
   prior chlamydial infection and, 71, 317  
   with single vs. multiple occurrences, 48  
   prior gonococcal infection and, 71

## U

- Uganda, genital herpes and genital ulcer disease in, 351  
 University students, HIV/AIDS risk reduction education for, 104  
 Urethral swabs, *C. trachomatis* detection in, vs. in urine, 55  
 Urethritis, male  
   chlamydial, 244  
   with/without discharge, 244  
 Urine, male, *C. trachomatis* detection in, 55

## V

- Vagina, *Lactobacilli* colonization of, after treatment for vaginitis and cervicitis, 269  
 Vaginitis, antibiotics for, *Lactobacilli* colonization after, 269  
 Vaginosis, bacterial  
   antibiotics for, *Lactobacilli* colonization after, 269  
   cervical intraepithelial neoplasia and, 296  
 Video-based education, for condom acquisition, 97  
 Vulvovaginal candidiasis, fluconazole vs. clotrimazole for, 228

## Y

- Yeast vaginosis, antibiotics for, *Lactobacilli* colonization after, 269

## Z

- Zimbabwe, STD and HIV prevalence in, 1

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970; Section 3685. Title 39 United States Code)  
 Date of Filing—October 1, 1995. Title of Publication—SEXUALLY TRANSMITTED DISEASES; Frequency of Issue—Bimonthly; Annual Subscription Price—\$150.00; Location of Known Office of Publication—12107 Insurance Way, Suite 114, Hagerstown, MD 21740; Location of the Headquarters of General Business Offices or the Publisher—Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106; Publisher—Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106; Editor—Julius Schachter, M.D., 1001 Potrero Ave., Bldg. 30, Room 416, S.F. General Hospital, San Francisco, CA 94110; Managing Editor—Jeanne Moncada, 1001 Potrero Ave., Bldg. 30, Room 416, S. F. General Hospital, San Francisco, CA 94110; Owner—American Venereal Disease Association, c/o Denver Public Health, 605 Bannock St., Denver, CO 80204; Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—None. A. Total no. copies printed (*net press run*), average 2,017, actual 2,000; B. Paid circulation none. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 1,456, actual 1,414; C. Total paid circulation, average 1,456, actual 1,414; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 59, actual 61; E. Free distribution outside the mail, average, none, actual none. F. Total free distribution (*sum of D and E*), average 59, actual 61. G. Total distribution (*sum of C and F*), average 1,515, actual 1,475; H. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 502, actual 525. 2. Returns from news agents, none; I. Total (*Sum of G, H1 and H2*), average 2,017, actual 2,000. I certify that the statements made by me above are correct and complete. Virginia B. Martin. Vice President, Operations.

